Medindia
Medindia LOGIN REGISTER
Advertisement

Medicinal Cannabis Industry Turns Toward Biopharma Influence for Competitive Advantages in Product Development

Thursday, February 16, 2017 Drug News
Advertisement
PALM BEACH, Florida, February 16, 2017 /PRNewswire/ --
Advertisement

While the medicinal cannabis industry continues to rapidly advance and expand operations by identifying new leading edge products, leaders are turning towards the expertise and knowledge of other medical sectors, especially with influence from the biopharma sector. Medical Marijuana and legal cannabis companies in the markets with recent developments and performance of note include: INSYS Therapeutics, Inc. (NASDAQ: INSY), Vinergy Resources Ltd (OTC: VNNYF) (CSE: VIN.CN), Canopy Growth Corporation (OTC: TWMJF) (TSX: WEED.TO), Aurora Cannabis Inc. (OTC: ACBFF) (TSX-V: ACB.V), Aphria Inc. (OTC: APHQF) (TSX-V: APH.V).
Advertisement

Vinergy Resources Ltd (OTCQB: VNNYF) (CSE:VIN), in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce that, as a part of the Company's strategy to develop a lab for research and development products that test and identify specific cannabinoid isolates for targeted therapeutic purposes, it has appointed John Simon to the Company's Scientific Advisory Board (SAB). John has a Bachelor of Science from the University of Alberta, is a senior member of the American Society for Quality, a Certified Quality Auditor (CQA), a Registered Quality Assurance Professional in Good Laboratory Practice (RQAP-GLP) and maintains Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society. Read this and more news for Vinergy Resources at: http://marketnewsupdates.com/news/vnnyf.html

Through John's consultancy practice, he assists companies with both site licenses and product licenses. He has helped companies obtain, renew and maintain in good standing Drug Establishment Licenses (DEL); Medical Device Establishment Licenses (MDEL); Natural and Non-prescription Site Licenses (NNHPD); and Licenses to Cultivate and Distribute under the Marihuana for Medical Purposes Regulations (MMPR) (now under the ACMPR). "With John's substantial background in QA and regulatory affairs specific to drug development and the cannabis industry, he will be a key asset in driving our cannabis product and technology initiatives," said Mr.Kent Deuters, CEO of MJ Biopharma.

Vinergy Resources also announced this week a major breakthrough while conducting research and development on oral cannabinoid complex (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabinol (CBN) and Terpenes) delivery strips and controlled time release capsule technology. This novel approach will be the basis for several products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of the cannabinoid complex into the body.

In other cannabis - legal marijuana market performances and developments of note include: 

Aurora Cannabis Inc. (OTCQB: ACBFF) (TSX-V: ACB.V) a dually-listed company on Wednesday closed up on the OTC markets at $1.96 trading over 500,000 shares and closed even on the TSX at $2.56 trading over 2.6 million shares by the market close. Aurora Cannabis and Radient Technologies (RTI.V) this week provided an update on their previously announced collaboration arrangements. Read the full announcement at http://finance.yahoo.com/news/aurora-cannabis-radient-technologies-exclusive-124000123.html

Canopy Growth Corporation (OTC: TWMJF)(TSX: WEED.TO) this week released its financial results for the third quarter of fiscal year 2017, the period ended December 31 , 2016. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Consolidated financial results include the accounts of the Company and its wholly-owned subsidiaries which include Tweed Inc. ("Tweed"), Tweed Farms Inc. ("Tweed Farms"), and Bedrocan Canada Inc. ("Bedrocan Canada") and its investments in affiliates. Read the full report at http://finance.yahoo.com/news/canopy-growth-corporation-reports-third-113000287.html

Aphria Inc. (OTCQB: APHQF) (TSX-V: APH.V) a dually listed company on Wednesday closed up on the OTC markets at $5.01 trading over 400,000 shares and closed up on the TSX at $6.52 trading over 4.8 million shares by the market close. Aphria, one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available.

INSYS Therapeutics, Inc. (NASDAQ: INSY) closed up over 12% on Wednesday at $10.82 trading over 3.2 Million shares by the market close. Insys Therapeutics this week announced that the Company is providing for the use of Cannabidiol Oral Solution at doses up to 40 mg/kg/day in compassionate use studies in subjects with refractory pediatric epilepsy following completion of 48 weeks of treatment in the ongoing long-term safety study. The long-term safety study permitted subjects who had completed the initial safety and pharmacokinetic (PK) study to receive Cannabidiol Oral Solution at doses up to 40 mg/kg/day for up to 48 weeks.

DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Vinergy Resources Ltd by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information: Media Contact email: [email protected] +1(561)325-8757

SOURCE Marketnewsupdates.com

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close